Every 8-K that Structure Therapeutics Inc. American (GPCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPCR filings page.
Structure Therapeutics Inc. (GPCR) reported positive clinical updates for its two lead oral obesity candidates, the amylin agonist ACCG‑2671 and the GLP‑1 receptor agonist aleniglipron. ACCG‑2671’s Phase 1/2a single‑ascending‑dose study in 31 healthy adults showed a ~6‑day half‑life, dose‑proportional exposure, and no serious adverse events or drug‑induced liver injury.
A single 10 mg dose of ACCG‑2671 produced a 3.3% mean body‑weight reduction at Day 24 and about a 60% drop in CTX‑1, supporting target engagement; gastrointestinal events appeared at 5–10 mg and are guiding titration in an ongoing 12‑week multiple‑dose trial, with topline data expected in the first half of 2027.
Aleniglipron’s 72‑week ACCESS open‑label extension showed continued weight loss, with participants from the 120 mg arm titrated to 180 mg achieving 16.2% mean weight loss, and more than one‑third of those in the 90 mg and 120 mg cohorts exceeding 20% body‑weight reduction, while fewer than 5% discontinued due to adverse events. A “start‑low, go‑slow” titration from 2.5 mg improved gastrointestinal tolerability. Aleniglipron is now in two global Phase 3 ACCOMPLISH trials enrolling about 3,600 and 1,100 patients, with topline data expected in the second half of 2028.
Structure Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026 and highlighted advances in its obesity-focused pipeline. First patients were dosed in the Phase 3 ACCOMPLISH program evaluating aleniglipron, a once-daily oral GLP-1 receptor agonist, for chronic weight management. Phase 2b ACCESS data, published in Nature Medicine and presented at the ADA Scientific Sessions, showed dose-dependent, clinically meaningful and statistically significant body-weight reductions, with weight loss up to 16.2% at 44 weeks in an open-label extension and an overall discontinuation rate of 10.4%.
The company is also progressing ACCG-2671, an oral dual amylin and calcitonin receptor agonist, with Phase 1 single ascending dose data and a multiple ascending dose trial planned for the third quarter of 2026, and additional aleniglipron and GLP-1/amylin combination data in the second half of 2026. Cash, cash equivalents and short-term investments were $1.3 billion as of June 30, 2026, which Structure Therapeutics expects will fund projected operations and key clinical milestones through the end of 2028. In the second quarter of 2026, research and development expenses were $100.1 million, general and administrative expenses were $18.6 million, and net loss totaled $106.2 million.
Structure Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on June 17, 2026. As of the April 20, 2026 record date, 213,213,565 ordinary shares were outstanding and entitled to vote. Shareholders elected Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch as Class III directors, each to serve until the 2029 annual meeting.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote, shareholders approved the compensation of the company’s named executive officers as described in the proxy statement for the meeting.
Structure Therapeutics Inc. amended and restated its at-the-market sales agreement with Leerink Partners and Cantor Fitzgerald, supported by a prospectus supplement that increases potential ADS sales by an additional $150,000,000, for an aggregate offering price of up to $400,000,000.
The company reported positive Phase 2 ACCESS II results for obesity drug aleniglipron, with up to 16.3% body weight loss at 44 weeks and favorable FDA end-of-Phase 2 feedback, and plans to initiate Phase 3 in Q3 2026. Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, including a $100.0 million upfront license fee, funding operations through the end of 2028, while Q1 2026 R&D expenses rose to $66.5 million and net loss reached $76.0 million.
Structure Therapeutics Inc. appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. He brings more than 15 years of executive experience at biopharmaceutical companies including Metsera, Lyell Immunopharma, Myovant Sciences and Gilead Sciences, as well as prior law firm experience.
Under his employment agreement, Mr. Lang will receive a base salary of $560,000 per year and an annual discretionary bonus targeted at 40% of salary, with no pro‑ration for 2026. He will be granted an option to purchase 223,776 ordinary shares, time-based RSUs for 184,614 ordinary shares and performance-based RSUs for 46,155 ordinary shares, all subject to multi-year vesting tied to service and specified performance milestones through 2029.
Structure Therapeutics reported strong Phase 2 obesity data for its once-daily oral GLP‑1 receptor agonist aleniglipron from the ACCESS program. In the ACCESS II trial, placebo‑adjusted mean weight loss at 44 weeks reached 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg, with no evidence of weight‑loss plateau. An open‑label extension showed continued loss up to 16.2% (40.5 lbs) at 120 mg by week 56. Interim results from a body composition study using a lower 2.5 mg starting dose showed about 6.8% weight loss at a 20‑week median follow‑up and substantially fewer adverse‑event‑related discontinuations versus a 5 mg start. Across more than 625 participants, aleniglipron showed no drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. The company has an End‑of‑Phase 2 FDA meeting scheduled in the second quarter of 2026 and expects to start Phase 3 in the second half of 2026.
Structure Therapeutics Inc. reported its fourth quarter and full-year 2025 results and provided a pipeline update focused on obesity treatments. Positive Phase 2 aleniglipron data showed significant weight loss across all doses, reaching up to 15.3% at 36 weeks, supporting advancement into Phase 3, which is expected to start in the second half of 2026.
The company reported cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, which it expects to fund operations and key clinical milestones through the end of 2028. Fourth quarter 2025 R&D expenses were $68.7 million and full-year R&D totaled $225.3 million, reflecting expanded clinical activity. Other license income of $100.0 million and $10.2 million of gains on sale of non-financial assets contributed to fourth quarter 2025 net income of $33.0 million, compared to a net loss of $36.5 million a year earlier. For full-year 2025, the company recorded a net loss of $141.2 million, compared to a net loss of $122.5 million in 2024.
Structure Therapeutics Inc. furnished a current report describing a new press release that provides a corporate update and the company’s financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for those detailed results.
The report clarifies that this information, including Exhibit 99.1, is furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.